{
  "id": "588fa4b9ed9bbee70d000006",
  "type": "yesno",
  "question": "Is ocrelizumab effective for treatment of multiple sclerosis?",
  "ideal_answer": "Yes, ocrelizumab is effective for primary progressive form of multiple sclerosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27270678",
    "http://www.ncbi.nlm.nih.gov/pubmed/21341224",
    "http://www.ncbi.nlm.nih.gov/pubmed/24494635",
    "http://www.ncbi.nlm.nih.gov/pubmed/27116720",
    "http://www.ncbi.nlm.nih.gov/pubmed/22047971",
    "http://www.ncbi.nlm.nih.gov/pubmed/25887773",
    "http://www.ncbi.nlm.nih.gov/pubmed/26600872",
    "http://www.ncbi.nlm.nih.gov/pubmed/27718747",
    "http://www.ncbi.nlm.nih.gov/pubmed/24494619",
    "http://www.ncbi.nlm.nih.gov/pubmed/27552111",
    "http://www.ncbi.nlm.nih.gov/pubmed/27813441",
    "http://www.ncbi.nlm.nih.gov/pubmed/18951300",
    "http://www.ncbi.nlm.nih.gov/pubmed/24732658",
    "http://www.ncbi.nlm.nih.gov/pubmed/27389598",
    "http://www.ncbi.nlm.nih.gov/pubmed/25888198",
    "http://www.ncbi.nlm.nih.gov/pubmed/23609782",
    "http://www.ncbi.nlm.nih.gov/pubmed/22229582",
    "http://www.ncbi.nlm.nih.gov/pubmed/25887766",
    "http://www.ncbi.nlm.nih.gov/pubmed/26729332",
    "http://www.ncbi.nlm.nih.gov/pubmed/24928997",
    "http://www.ncbi.nlm.nih.gov/pubmed/20500147",
    "http://www.ncbi.nlm.nih.gov/pubmed/27756172",
    "http://www.ncbi.nlm.nih.gov/pubmed/26702336",
    "http://www.ncbi.nlm.nih.gov/pubmed/22673950",
    "http://www.ncbi.nlm.nih.gov/pubmed/26788130",
    "http://www.ncbi.nlm.nih.gov/pubmed/25732947",
    "http://www.ncbi.nlm.nih.gov/pubmed/24507535"
  ],
  "snippets": [
    {
      "text": " Advances made in immunomodulation are driving the progress being made in the treatment of MS. Ocrelizumab is the first treatment with positive results in the primarily progressive forms and tocilizumab, a drug product for rheumatoid arthritis, stands out as a potential candidate for the treatment of neuromyelitis optica.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27270678",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Expert commentary: The recent encouraging results of the ocrelizumab trial in PP MS, the first to reach the primary disability endpoint, indicate B cells as a promising therapeutic target to prevent disease progression. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813441",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Expert commentary: The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The efficacy of three of them, rituximab, ocrelizumab and ofatumumab in MS has been confirmed by placebo-controlled clinical trials demonstrating a significant reduction of the annualized relapsing rate (ARR), new gadolinium-enhancing (GdE) and T2 lesions. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27718747",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ongoing PMS trials are currently being conducted with the phosphodiesterase inhibitor ibudilast, S1P modulator siponimod and anti-B-cell therapy ocrelizumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887766",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-\u03b2-1a, and three times weekly glatiramer acetate. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887773",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To summarize mechanisms of action, efficacy, and safety of novel and imminently emerging disease-modifying treatments (DMTs) intended to be used in relapsing-remitting multiple sclerosis (RRMS).Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-\u03b2-1a, and three times weekly glatiramer acetate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887773",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In multiple sclerosis (MS), B cell-depleting therapy using monoclonal anti-CD20 Abs, including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928997",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.Most of the presented cell-depleting and myeloablative therapies are highly effective treatment options but are also accompanied by significant risks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The armamentarium of approved disease-modifying therapies in MS and those in development include: (1) the first approved, moderately effective, injectable interferon-\u03b2 and glatiramer acetate; (2) oral drugs (fingolimod, laquinimod, teriflunomide, dimethyl fumarate); (3) monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, daclizumab, alemtuzumab); and (4) immunosuppressive agents (e.g. mitoxantrone).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24732658",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis.METHODS: We did a multicentre, randomised, parallel, double-blind, placebo-controlled study involving 79 centres in 20 countries. Patients aged 18-55 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1:1:1) via an interactive voice response system to receive either placebo, low-dose (600 mg) or high-dose (2000 mg) ocrelizumab in two doses on days 1 and 15, or intramuscular interferon beta-1a (30 \u00ecg) once a week.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788130",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.biosemantics.org/jochem#4002285",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103",
    "http://www.disease-ontology.org/api/metadata/DOID:2377"
  ],
  "exact_answer": "Yes"
}